Clodronate Liposomes (Neutral) and Control Liposomes | F70101C-NC-2 | 2 mL +2mL | 3104.00 |
Clodronate Liposomes (Neutral) and Control Liposomes | F70101C-NC-10 | 10 mL +10mL | 10915.00 |
Clophosome® -N is a multilamellar liposome suspension in which clodronate is encapsulated in the aqueous compartments of the liposomes. The control is formulated and prepared identically to Clodrosome®-N except that clodronate is not added to the liposomes. Both are prepared and packaged under sterile conditions. When animals or cells are treated with Clodrosome®-N, phagocytic cells recognize the liposomes as invading foreign particles and proceed to remove the liposomes from the local tissue or serum via phagocytosis. The liposomes then release clodronate into the cytosol, resulting in cell death. Non-encapsulated clodronate cannot cross the cell membrane to initiate cell death.
• white milky suspensions
• suitable for dosing with various routes
• standard neutral clodronate liposomes kit
| Product Name | SKU | Unit Size | Price(￥) |
Clodronate Liposomes (Neutral) and Control Liposomes | F70101C-NC-2 | 2 mL +2mL | 3104.00 |
Clodronate Liposomes (Neutral) and Control Liposomes | F70101C-NC-10 | 10 mL +10mL | 10915.00 |
Clophosome®-N & Control Liposomes
Included in this convenience combo kit are 1 vial of the neutral clodronate liposomes and 1 vial of control liposomes. When animals or cells are treated with chlorate liposomes, phagocytes will remove liposomes from local tissue or serum by phagocytosis. Liposomes are then able to release clodronate into the cytoplasm, causing cell death. Unencapsulated clodronate cannot cross cell membranes to trigger cell death.
The product is suitable for dosing with various routes including intravenous, intraperitoneal, subcutaneous, intranasal, intratracheal and etc. We have achieved 80-90% macrophage depletion in spleen (red pulp macrophages) 24 hours after a single 0.2 mL intravenous injection. A starting dose of 0.15 - 0.2 mL (i.v. or i.p.) for 20-25g animal body weight is recommended for good consistency in macrophage depletion. Optimization is recommended for your specific applications.
Specifications
Details: Each Standard Clodronate Liposomes Kit is composed of one vial of clodronate liposome and one vial of control liposome
Lipid Composition: Phosphatidylcholine and Cholesterol
Mean Particle Size: 1.5-2 µm
Encapsulated Drug: Clodronate disodium; CAS 22560-50-5, 7 mg/mL
Buffer: Phosphate buffered saline
pH: 7.0-7.5
Shelf Life: 6 months guaranteed for unopened vials at 2-8 °C
Storage： Stored at in the dark at 4°C and NEVER be frozen.
Shipping： Shipped on blue ice at 4°C in insulated packages
Note: If left idle in the refrigerator, phase separation occurs (precipitate forms at the bottom of the vial, leaving a clear solution on top). Before use, shake gently to form a homogeneous solution to avoid the formation of air bubbles.
1. van Rooijen N, van Nieuwmegen R. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study. Cell Tissue Res. 1984;238(2):355-8. doi: 10.1007/BF00217308. PMID: 6239690. View Article
2. van Rooijen N, van Nieuwmegen R, Kamperdijk EW. Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. Ultrastructural aspects of elimination of marginal zone macrophages. Virchows Arch B Cell Pathol Incl Mol Pathol. 1985;49(4):375-83. doi: 10.1007/BF02912114. PMID: 2867636. View Article
3. Claassen E, Kors N, van Rooijen N. Immunomodulation with liposomes: the immune response elicited by liposomes with entrapped dichloromethylene-diphosphonate and surface-associated antigen or hapten. Immunology. 1987 Apr;60(4):509-15. PMID: 2953668; PMCID: PMC1453280. View Article
4. van Rooijen N, Kors N, ter Hart H, Claassen E. In vitro and in vivo elimination of macrophage tumor cells using liposome-encapsulated dichloromethylene diphosphonate. Virchows Arch B Cell Pathol Incl Mol Pathol. 1988;54(4):241-5. doi: 10.1007/BF02899217. PMID: 2895535. View Article
5. van Rooijen N, Kors N, Kraal G. Characterization of cell populations, reappearing in the mouse spleen after elimination by liposome encapsulated dichloromethylene diphosphonate: reappearance of marginal zone lymphocytes is independent of marginal zone macrophages. Adv Exp Med Biol. 1988;237:889-93. doi: 10.1007/978-1-4684-5535-9_133. PMID: 2978212. View Article
6. van Rooijen N, Kors N, Kraal G. Macrophage subset repopulation in the spleen: differential kinetics after liposome-mediated elimination. J Leukoc Biol. 1989 Feb;45(2):97-104. doi: 10.1002/jlb.45.2.97. PMID: 2521666. View Article
7. Su D, Van Rooijen N. The role of macrophages in the immunoadjuvant action of liposomes: effects of elimination of splenic macrophages on the immune response against intravenously injected liposome-associated albumin antigen. Immunology. 1989 Mar;66(3):466-70. PMID: 2703258; PMCID: PMC1385238. View Article
8. Thepen T, Van Rooijen N, Kraal G. Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice. J Exp Med. 1989 Aug 1;170(2):499-509. doi: 10.1084/jem.170.2.499. PMID: 2526847; PMCID: PMC2189410. View Article
